Immune-related responses*
| All treated patients N=50 | Progressed on prior anti-PD-1 therapy n=33 | No prior anti-PD-1 therapy n=17 | |
| Objective response rate, % (95% CI) | 30 (18 to 45) | 21 (9 to 39) | 47 (23 to 72) |
| Complete response, n (%) | 5 (10) | 2 (6) | 3 (18) |
| Partial response, n (%) | 10 (20) | 5 (15) | 5 (29) |
| Stable disease, n (%) | 17 (34) | 15 (45) | 2 (12) |
| Progressive disease, n (%) | 16 (32) | 11 (33) | 5 (29) |
| Not evaluable, n (%) | 2 (4) | 0 | 2 (12) |
| Time to initial response, median (range), mo | 3.4 (0.7‒5.1) | 3.5 (3.2‒5.1) | 3.4 (0.7‒3.4) |
| Disease control rate†, n (%) | 32 (64) | 22 (67) | 10 (59) |
| Durable response rate‡, % (95% CI) | 14 (6 to 27) | 12 (3 to 28) | 18 (4 to 43) |
| Duration of response | |||
| Median (95% CI), months | 8.8 (5.9 to 8.8) | 8.8 (5.9 to 8.8) | NR (4.9 to NR) |
| ≥6 months, % | 81 | 80 | 86 |
*Data analyzed in the safety analysis set; responses are based on investigator assessment per immune-related response criteria.
†Complete response+partial response+stable disease.
‡Response lasting ≥6 months.
anti-PD-1, antiprogrammed death 1; NR, not reached.